L••• S•••••• L•••••••• I•• M•••••• D••••• R•••••• A••••••••

group grade Aon a schedule nowsponsor unattributed

What matters now

34¢ → 32¢
consensus mark
Consensus mark 32¢ on cost, down from 34¢ in Q4 2025.
Q2 2026 · The lenders' own valuations, the most direct read of what they expect to recover.
Derived1 of 1 lender' own marks, weighted by principal

Mark path, consensus per quarter end

34¢ · 32¢Q4 2025 to Q2 2026

Principal held

unknown

sum of BDC pieces, a lower bound

Fair value

$351,000

n/a on cost, debt pieces

Unfunded

Not disclosed

commitments not yet drawn

BDC lenders

1 on the latest quarter

Facilities

1 equity pieces beside them

Next maturity

unstated

no dated debt inside 24 months

On the tape since

Dec 31, 2025

latest Jun 30, 2026

Events

dated, non-routine

Lender marks

each lender's own fair value over cost at Jun 30, 2026, folded to one row per lender

Lender	Exposure	Current mark	QoQ change
H•••••• T••••••••• F•••••• C•••	no principal filed	32¢	-2 pts

Every BDC piece · 1 position across 1 lenderlargest principal first, with instrument and rate

BDC	Instrument	Principal	Fair value	Rate
H•••••• T••••••••• F•••••• C•••	unstated lien unstated	Not disclosed	$351,000 32c

Capital structure as the BDCs see it

latest quarter end Jun 30, 2026

No debt facility on the tape for this borrower; the BDC pieces are equity.

Equity pieces beside the debt: other ($351,000 fair value, 1 BDC)

Through time

the borrower's pieces summed across BDCs, every quarter end

Quarter end	BDCs	Principal held	Fair value	On cost	PIK pieces
Jun 30, 2026	1	$0	$0	n/a	0
Dec 31, 2025	1	$0	$0	n/a	0

What changed

Identity

Group key: LIFE SCIENCE LUMITHERA MEDICAL DEVICE ROYALTY AGREEMENTderivedthe codename stem after legal suffixes and deal words
Spellings: 1 across 1 BDCderived